Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about 4D MOLECULAR THERAPEUTICS, INC.
11/234D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2021 C..
AQ
11/104D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and P..
PU
11/104D Molecular Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine..
CI
11/10Earnings Flash (FDMT) 4D MOLECULAR THERAPEUTICS Reports Q3 Revenue $1.4M
MT
11/104D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and P..
AQ
10/294D Molecular Therapeutics Prices Stock Offering at $25 Per Share; Shares Decline
MT
10/294D Molecular Therapeutics Prices Stock Offering at $25 Per Share
MT
10/284D Molecular Therapeutics Announces Pricing of Public Offering of Common Stock
GL
10/274D Molecular Therapeutics Commences Public Offering of 4.5 Million Common Shares
MT
10/264D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
GL
10/264D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
GL
10/254D MOLECULAR THERAPEUTICS : 4D-310 & 4D-110 Clinical Data Conference Call Presentation
PU
10/254D MOLECULAR THERAPEUTICS : Reports Interim Results from the 4D-310 Phase 1/2 Clinical Tri..
AQ
10/254D Molecular Therapeutics, Inc. Reports Interim Results from the 4D-310 Phase 1/2 Clini..
CI
10/25INSIDER SELL : 4d Molecular Therapeutics
MT
More most relevant news
All news about 4D MOLECULAR THERAPEUTICS, INC.
11/234D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2021 C..
AQ
11/104D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and P..
PU
11/104D MOLECULAR THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condi..
AQ
11/104D Molecular Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine..
CI
11/10Earnings Flash (FDMT) 4D MOLECULAR THERAPEUTICS Reports Q3 Revenue $1.4M
MT
11/104D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and P..
AQ
10/294D Molecular Therapeutics Prices Stock Offering at $25 Per Share; Shares Decline
MT
10/294D Molecular Therapeutics Prices Stock Offering at $25 Per Share
MT
10/284D Molecular Therapeutics Announces Pricing of Public Offering of Common Stock
GL
10/274D Molecular Therapeutics Commences Public Offering of 4.5 Million Common Shares
MT
More news
News in other languages on 4D MOLECULAR THERAPEUTICS, INC.
11/10Earnings Flash (FDMT) 4D MOLECULAR THERAPEUTICS annonce un chiffre d'affaires de 1,4 mi..
10/294D Molecular Therapeutics propose une offre d'actions à 25 dollars par action ; les act..
10/294D Molecular Therapeutics propose une offre d'actions à 25 dollars par action.
10/274D Molecular Therapeutics propose une offre publique de 4,5 millions d'actions ordinair..
10/11Le médicament 4D-125 de 4D Molecular Therapeutics montre son potentiel dans un essai su..
08/12Earnings Flash (FDMT) 4D MOLECULAR THERAPEUTICS annonce un chiffre d'affaires de 14,6 m..
06/244D Molecular déclare que Roche arrête l'essai et annule l'accord de licence pour le méd..
More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
01/054D MOLECULAR THERAPEUTICS : BofA Securities Starts 4D Molecular Therapeutics at Buy With $..
MT
01/054D MOLECULAR THERAPEUTICS : Evercore ISI Starts 4D Molecular Therapeutics at Outperform Wi..
MT
01/054D MOLECULAR THERAPEUTICS : Goldman Sachs Starts 4D Molecular Therapeutics at Neutral With..
MT
More recommendations
Press releases
11/234D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2021 C..
AQ
11/104D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and P..
PU
11/104D MOLECULAR THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condi..
AQ
11/104D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and P..
AQ
10/284D Molecular Therapeutics Announces Pricing of Public Offering of Common Stock
GL
More press releases